Mallinckrodt PLC

Most Recent

  • uploads///operational paramets
    Earnings Report

    Can Valeant’s Margins for 2Q16 Meet Expectations?

    During 4Q15 and 1Q16, Valeant Pharmaceuticals’ (VRX) net margin turned negative. That followed its struggling high-margin dermatology products and the foreign exchange impact.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Endo International’s and Mallinckrodt’s EPS Growth Expectations

    In its fourth-quarter investor presentation, Endo International (ENDP) guided for adjusted diluted EPS and adjusted EBITDA of $2.00–$2.25 and $1.24 billion–$1.34 billion, respectively, in fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Wall Street Has Mixed Opinions on Mallinckrodt

    Wall Street analysts expect upside potential of 35.45% for Mallinckrodt (MNK), based on the company’s closing price on March 22.

    By Margaret Patrick
  • uploads///MNK
    Fund Managers

    Adage Capital adds a new position in Mallinckrodt

    Adage Capital added a new position in Mallinckrodt Plc (MNK) in the third quarter of 2014. The position accounted for 0.82% of the fund’s total portfolio.

    By Samantha Nielson
  • uploads///holdings in valeant
    Company & Industry Overviews

    What Does Valeant’s Institutional Ownership Look Like?

    Of its total outstanding shares, Valeant Pharmaceuticals’ (VRX) institutional ownership stood at 69.2%.

    By Jillian Dabney
  • uploads///US dollar has been strengthening
    Macroeconomic Analysis

    Stronger Dollar Hampers US Trade Balance; SPY Falls 1.15%

    According to the US trade balance report, the US trade deficit widened to $51.37 billion in March against an expected $41.7 billion. March is the largest monthly widening since 1996.

    By Surbhi Jain
  • uploads///MArket opportunity for Acthar
    Company & Industry Overviews

    Inside Mallinckrodt’s Major Valuation Catalysts

    Acthar is Mallinckrodt’s (MNK) leading product, and the company plans to achieve mid-single-digit to low-double-digit growth for the drug in fiscal 2016.

    By Jillian Dabney
  • uploads///US Quarterly Economic Growth
    Macroeconomic Analysis

    The US Economy: Fischer and Brainard Weigh In

    Stanley Fischer expressed his views on the US economy at the G30 Annual International Banking Seminar on October 11. This came three days after the dovish minutes of the FOMC September meeting.

    By David Ashworth
  • uploads///pe
    Company & Industry Overviews

    Is Valeant a Good Bet on a Price-to-Earnings Basis?

    On August 11, 2016, Valeant Pharmaceuticals (VRX) was trading at a forward PE (price-to-earnings) multiple of ~3.0x.

    By Jillian Dabney
  • uploads///fin projections
    Earnings Report

    What to Expect from Valeant’s Upcoming Q216 Earnings

    Wall Street analysts anticipate that Valeant will record $2.47 billion and $2.54 billion total revenue for 2Q16 and 3Q16, respectively.

    By Jillian Dabney
  • uploads///segemnts and margins
    Company & Industry Overviews

    Yes, There Will Be Margin Erosion for Valeant in 2017

    Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.

    By Jillian Dabney
  • uploads///pulse trace _
    Company & Industry Overviews

    Analyst Ratings for Endo International and Peers in August

    In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY decline of 18.4%.

    By Margaret Patrick
  • uploads///revenue ee
    Earnings Report

    How Did Valeant Fare in 2Q16?

    Valeant Pharmaceuticals (VRX) announced earnings for 2Q16 on August 9, 2016.

    By Jillian Dabney
  • uploads///AAL
    Financials

    Magnetar decreases stakes in American Airlines

    Magnetar reduced its position in AAL in the third quarter. The position accounts for 1.17% of the fund’s total portfolio in the third quarter.

    By Patricia Garner
  • uploads///s
    Company & Industry Overviews

    Citron Research Tweet Pulled NVIDIA Prices Lower on December 28

    The S&P 500 Information Technology sector fell 0.87% on December 28. NVIDIA (NVDA) and First Solar (FSLR) were the top losers.

    By Val Kensington
  • uploads///revenue margin projections
    Company & Industry Overviews

    Projected Revenue for Valeant in 2017

    Valeant Pharmaceuticals (VRX) has been keeping an eye on the progress of its dermatology and gastrointestinal portfolio.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Quest Gains after Acquisition of Clinical Laboratory Partners

    Quest Diagnostics (DGX) gained 2.9% on March 1, 2016, as it announced the completion of Outreach Laboratory

    By Peter Neil
  • uploads///PE
    Company & Industry Overviews

    How Is Valeant Trading at a Discount on PE Basis?

    On March 16, Valeant Pharmaceuticals was trading at a forward PE multiple of 2.94x. This appears to be a significant discount compared to peers.

    By Jillian Dabney
  • uploads///SPY versus Oil Gold Copper Treasury and Materials
    Macroeconomic Analysis

    SPY Falls 2.51% on Global Uncertainty

    The SPDR S&P 500 ETF (SPY) fell by 2.51% on Monday, September 28, 2015, while the Direxion Daily S&P 500 Bull 2X ETF (SPUU) fell by 4.95%.

    By Renee Blakely
  • Healthcare

    Why dividend recapitalization is the sweet spot for leveraged loans

    While M&A activity was still below market prospects, demand for dividend recapitalization deals was mostly strong last week.

    By Sandra Nathanson
  • uploads///ANR
    Company & Industry Overviews

    What Do Analysts Recommend for Valeant after Recent Happenings

    The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.

    By Jillian Dabney
  • uploads///revenue ee
    Earnings Report

    Understanding Mallinckrodt’s Impressive Revenue and Earnings in 2Q16

    Wall Street analysts expected Mallinckrodt’s revenues for fiscal 2Q16 to be ~$871.5 million, but Mallinckrodt surprised them with sales of $918 million.

    By Jillian Dabney
  • uploads///Three share prices
    Earnings Report

    The Many Reasons Mylan Is So Keen to Acquire Perrigo

    On April 21, 2015, Teva (TEVA) launched a proposal to acquire Mylan for $82 a share in a 50% cash, 50% stock deal worth $43 billion. Mylan rejected the offer.

    By Nicole Sario
  • uploads///generics
    Earnings Report

    Inside the Double-Digit Fall for Mallinckrodt’s Specialty Generics Business in 2016

    Specialty Generics’ contribution to Mallinckrodt’s net sales fell by 18% to $1 billion in 2016. The business had a 31% share in total net sales in 2016.

    By Jillian Dabney
  • uploads///Geographic exposure
    Company & Industry Overviews

    Central Nervous System Is Key to Teva’s Specialty Medicines

    Revenues for Teva’s (TEVA) Specialty Medicines segment grew by 2.1% to $8,560 million in 2014, from $8,388 million in 2013.

    By Nicole Sario
  • uploads///EV to EBITDA
    Company & Industry Overviews

    What Valeant’s EV-to-EBITDA Multiple Means

    Valeant Pharmaceuticals was trading at a forward EV-to-EBITDA multiple of 5.64x on March 16. This looks to be a huge discount when compared peers.

    By Jillian Dabney
  • uploads///operating segments
    Earnings Report

    A Look at Mallinckrodt’s Operating Segments

    Mallinckrodt (MNK) is a specialty pharmaceuticals company that relies on volume-driven growth. Let’s discuss the performances of its three segments.

    By Jillian Dabney
  • uploads///ETFs
    Company & Industry Overviews

    ETFs Capitalize on the Generic Industry’s Growth

    ETFs are the investment funds—like index funds and mutual funds—that track an index, a commodity, or a basket of assets. ETFs are publicly traded on an exchange.

    By Nicole Sario
  • uploads///Chart
    Macroeconomic Analysis

    Analyzing SPY’s Stocks, Noble and ENSCO Rose

    On December 15, the stocks at the top of the SPDR S&P 500 ETF (SPY) were ENSCO (ESV), Noble (NE), and Mallinckrodt (MNK). ENSCO rose by 8.0%.

    By Renee Blakely
  • uploads///tOP
    Company & Industry Overviews

    Mallinckrodt Was the S&P 500’s Top Gainer on May 26

    Mallinckrodt Pharmaceuticals, which produces specialty pharmaceutical products such as generic drugs and imaging agents, surged to a ten-day high on May 26.

    By Val Kensington
  • uploads///ElliottQ
    Energy & Utilities

    Overview: Assessing Elliott Management’s 2Q14 positions

    Paul Singer’s Elliott Management, a New York hedge fund, disclosed new positions in a 13F filed this month. In this series, we’ll discuss some of the notable positions the $24 billion activist fund traded in the second quarter of 2014 (or 2Q14).

    By Samantha Nielson
  • uploads///specialty brands
    Earnings Report

    How Mallinckrodt’s Specialty Brands Performed in 2Q16

    Mallinckrodt’s Specialty Brands segment earned $535 million during fiscal 2Q16 and includes Acthar, the lead drug, as well as other drugs.

    By Jillian Dabney
  • uploads///OUTR
    Basic Materials

    JANA Partners opens new positions in MNK, OUTR, NWSA, and HUN and sells HMA and AET—13F Flash B

    JANA Partners LLC is a value-oriented investment advisor specializing in event-driven investing exclusively for qualified investors. Why buy Outerwall Inc. (OUTR)?

    By Samantha Nielson
  • uploads///Adage
    Financials

    A key overview of Adage Capital’s holdings in 3Q14

    Adage Capital’s US long portfolio grew from $38.69 billion in 2Q14 to $40.2 billion in 3Q14. The portfolio comprised around 699 stocks.

    By Samantha Nielson
  • uploads///KMI
    Energy & Utilities

    Kinder Morgan’s position with Adage Capital eliminated

    Adage Capital exited a position in Kinder Morgan Inc (KMI) in the third quarter. The position accounted for 0.37% of the fund’s total 2Q portfolio.

    By Samantha Nielson
  • uploads///C
    Financials

    Citigroup gets raised position with Adage Capital

    Adage Capital raised its position in Citigroup Inc. (C) in the third quarter. The position accounted for 0.98% of the fund’s total 3Q portfolio.

    By Samantha Nielson
  • uploads///NI
    Energy & Utilities

    Adage Capital raises its position in NiSource

    Adage Capital raised its position in NiSource Inc. (NI) in the third quarter. The position accounted for 0.52% of the fund’s total 3Q14 portfolio.

    By Samantha Nielson
  • uploads///Graph
    Company & Industry Overviews

    What Could Drive Mallinckrodt’s Growth in Fiscal 2019

    In fiscal 2018, Mallinckrodt’s (MNK) revenue fell 0.19% YoY (year-over-year) to $3.22 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Endo’s and Mallinckrodt’s Expense Control Stacks Up

    In its fourth-quarter investor presentation, Endo International (ENDP) guided for its fiscal 2019 adjusted operating expenses as a percentage of revenue being 24.5%–25.0%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Comparing Endo’s and Mallinckrodt’s Revenue Forecasts

    In its fourth-quarter investor presentation, Endo International (ENDP) guided for fiscal 2019 revenue of $2.76 billion–$2.96 billion, representing a low single-digit percentage YoY (year-over-year) decline.

    By Margaret Patrick
  • uploads///human skeleton _
    Company & Industry Overviews

    Analysts’ Views on Endo International and Mallinckrodt

    Most analysts covering Endo International (ENDP) and Mallinckrodt (MNK) recommend “hold.” On March 5, Endo closed at $8.72, and Mallinckrodt closed at $22.39.

    By Margaret Patrick
  • uploads///Salix
    Company & Industry Overviews

    How Is Salix Pharmaceuticals Positioned in November?

    Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017.

    By Daniel Collins
  • uploads///baxter
    Company & Industry Overviews

    Baxter International Completes Its Mallinckrodt Assets Buy

    Baxter (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt for $185.0 million.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    How Mylan’s North America Segment Performed

    The North America segment reported a growth of 22% to $1.6 billion during 4Q16 from $1.3 billion during 4Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Performance of Incyte’s Jakafi in the United States

    Revenues for Jakafi rose more than 42.0% to $852.8 million in 2016, from $601.0 million in 2015.

    By Mike Benson
  • uploads///operating segments
    Earnings Report

    How Did Mallinckrodt’s Specialty Brands Perform in 2016?

    Specialty Brands had a 69% in Mallinckrodt’s total revenue in 2016, while Specialty Generics had a 31% share.

    By Jillian Dabney
  • uploads///revenue
    Earnings Report

    Mallinckrodt’s Revenue Growth in Fiscal 4Q16

    On an annual basis, MNK’s net sales soared by 16% to $3.4 billion in 2016. Despite its better-than-estimated performance, shares fell by 9% on November 29.

    By Jillian Dabney
  • uploads///specialty portfolio
    Company & Industry Overviews

    Mallinckrodt’s Greater Dependence on Acthar and Generic Business

    Mallinckrodt (MNK) has recently been making news due to its business model being questioned. A Citron Research report focused on the sustainability of Acthar’s higher level of exposure to government-oriented franchise.

    By Jillian Dabney
  • uploads///Acthar revunue
    Company & Industry Overviews

    Understanding Acthar’s Contribution to Mallinckrodt’s Top Line

    In 1Q16, Acthar earned $286.7 million for Mallinckrodt, reflecting a YoY jump of 7.6%. It accounted for 31% of the company’s total revenues in that quarter.

    By Jillian Dabney
  • uploads///PE
    Company & Industry Overviews

    Why Mallinckrodt Is Trading at a Discount on PE Basis

    On March 21, Mallinckrodt was trading at a forward PE multiple of 6.40x—an apparent discount compared to Johnson & Johnson and Teva.

    By Jillian Dabney
  • uploads///Acthar
    Company & Industry Overviews

    Where Else Have We Seen Mallinckrodt’s ‘Acquire to Invest’ Strategy?

    The business strategies of both Mallinckrodt and Valeant reflect what the former refers to as “Acquire to Invest.”

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Valeant Looks to Line Its Coffers Using These Five Strategies

    To boost profitability and share prices, Valeant plans to focus on five strategic imperatives to help it pose stronger competition to ENDP, MNK, and GILD.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Valeant Looks to Boost Profit Margins through the Walgreens Deal

    On December 15, 2015, Valeant Pharmaceuticals (VRX) announced its decision to enter into a fulfillment agreement with Walgreens.

    By Margaret Patrick
  • uploads///Teva regeneron
    Company & Industry Overviews

    Why Teva and Regeneron Entered Collaboration Agreement

    On September 20, 2016, Regeneron Pharmaceuticals (REGN) entered a collaboration agreement with Teva Pharmaceuticals (TEVA).

    By Jillian Dabney
  • uploads///burn product
    Company & Industry Overviews

    How StrataGraft Could Benefit Mallinckrodt’s Hospital Portfolio

    StrataGraft, if approved, will be the first biological off-the-shelf skin substitute for treating severe burns.

    By Jillian Dabney
  • uploads///acquisition
    Company & Industry Overviews

    What’s behind Mallinckrodt’s Stratatech Acquisition?

    Stratatech is a regenerative medicine company with a focus on the development of proprietary skin substitute products.

    By Jillian Dabney
  • uploads///margins
    Earnings Report

    Can Mallinckrodt Expand Its Margins?

    Wall Street analysts expect Mallinckrodt’s (MNK) net margin to jump to 24.3% in 3Q16 from 10% in 3Q15.

    By Jillian Dabney
  • uploads///ev to ebitda
    Company & Industry Overviews

    The Truth behind Horizon’s EV-to-EBITDA Performance

    On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Inside Neurocrine Biosciences’ Analyst Recommendations in 2016

    Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.

    By Margaret Patrick
  • uploads///Eculizumab
    Company & Industry Overviews

    What Are the Additional Labels for Alexion’s Soliris?

    Soliris is Alexion’s leading drug. It was approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in 2007 and 2011.

    By Jillian Dabney
  • uploads///nitropress and isuprel
    Company & Industry Overviews

    The Facts behind the Valeant Drug Pricing Controversy

    Valeant Pharmaceuticals International (VRX) significantly raised the prices of two of its heart drugs—Nitropress and Isuprel—which caused a controversy and an outrage.

    By Jillian Dabney
  • uploads///global brands
    Company & Industry Overviews

    What Happened in the Valeant-Philidor Controversy?

    Valeant’s (VRX) controversies started with Philidor, a specialty pharmacy company that was accused of altering doctor’s prescriptions so it could sell more of Valeant’s costly drugs.

    By Jillian Dabney
  • uploads///annual revenue
    Company & Industry Overviews

    Valeant: The Rise and Fall of a Giant Specialty Pharmaceutical

    Much of Valeant’s growth was coming from price increases rather than volume gains, and that wasn’t sustainable. The company’s steep price increases came under regulator scrutiny.

    By Jillian Dabney
  • uploads///Xtandi US sales
    Earnings Report

    Medivation: Xtandi Global Sales Rose 53% in 1Q16

    Xtandi is Medivation’s (MDVN) only commercialized asset. During the first quarter of 2016, the drug recorded revenue of $547.2 million.

    By Jillian Dabney
  • uploads///acthar
    Earnings Report

    What’s Driving Growth for Mallinckrodt’s Acthar?

    Acthar is Mallinckrodt’s (MNK) lead drug, which fetched $248.4 million, or 46%, of total sales for the company’s Specialty Brand segment.

    By Jillian Dabney
  • uploads///specialty generics
    Earnings Report

    What to Expect from Mallinckrodt’s Specialty Generics Business

    The total contribution from Mallinckrodt’s Specialty Generics segment in fiscal 2Q16 stood at $264.4 million, which represents a 27% YoY decline.

    By Jillian Dabney
  • uploads///VOD
    Company & Industry Overviews

    Defitelio: Volume and Pricing Challenges

    Jazz Pharmaceuticals’ Defitelio is the first and only approved treatment that increases survival in VOD patients with multi-organ dysfunction (or MOD).

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    XLV Mid-Cap Stocks: Why Mallinckrodt Fell Due to Profit-Booking

    Mallinckrodt (MNK) fell by 4.5% due to profit-booking. It closed at $58.40. The stock remained volatile on the backdrop of Valeant’s (VRX) episode.

    By Peter Neil
  • uploads///NPS Pharma acquisition
    Company & Industry Overviews

    How Has Shire Benefited from NPS Pharmaceuticals Acquisition?

    In February 2015, Shire (SHPG) completed its acquisition of NPS Pharmaceuticals for $5.2 billion. Through the merger, Shire gained access to Gattex and Natpara.

    By Jillian Dabney
  • uploads///Natpara
    Company & Industry Overviews

    Shire’s Acquisition Gives It Natpara and Gattex

    Gattex is the first and only analog of glucagon-like peptide-2 (or GLP-2) indicated for short bowel syndrome. The drug is known as Gattex in the United States and Revestive in Europe.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know

    Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.

    By Margaret Patrick
  • uploads///acquisitions
    Company & Industry Overviews

    How Horizon Became a Growth Stock

    Over the past 18 months, Horizon Pharma has acquired three orphan drugs. The acquisition of Hyperion Therapeutics in May 2015 gave it Ravicti and Buphenyl.

    By Jillian Dabney
  • uploads///Price to sales
    Company & Industry Overviews

    Why Is Horizon Trading at a Premium on a Price-to-Sales Basis?

    On March 24, Horizon Pharma was trading at a forward PS multiple of 2.18x. It appears to be trading at a premium next to Valeant, Mallinckrodt, and Endo.

    By Jillian Dabney
  • uploads///rare disease sales
    Company & Industry Overviews

    Rare Disease Portfolio Helped Sanofi to Offset Falling Diabetes Sales

    Genzyme, a subsidiary of Sanofi (SNY), holds rare disease, multiple sclerosis, oncology, and immunology disease drugs in its portfolio.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    XLV Mid-Cap Stocks Witness Profit-Booking

    The mid-cap stocks of the Health Care Select Sector SPDR ETF (XLV) fell collectively by 2.6%. They underperformed XLV as of March 8, 2016.

    By Peter Neil
  • uploads///Vimizim
    Company & Industry Overviews

    BioMarin’s Vimizim Sales Were up by 195% in 2015

    Vimizim contributed 26% to the top line of BioMarin Pharmaceutical in 2015. Meanwhile, the number of patients on Vimizim rose by 10% during 4Q15 over 3Q15.

    By Jillian Dabney
  • uploads///Chart
    Macroeconomic Analysis

    Healthcare Stock Mallinckrodt Emerged as One of the Top Stocks

    The stocks at the top of the SPDR S&P 500 ETF on December 30, 2015, were Allegheny Technologies (ATI), Mallinckrodt (MNK), and Tesoro Corporation (TSO).

    By Renee Blakely
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Eli Lilly Drags Down XLV’s Pharmaceutical Subgroup

    Eli Lilly (LLY) was the worst performer within the pharmaceutical subgroup as well as within XLV with a return of -3.0% on December 9, 2015.

    By Peter Neil
  • uploads///Chart
    Macroeconomic Analysis

    Which Stocks Are at the Top of SPY?

    The stocks at the top of the SPDR S&P 500 ETF (SPY) on November 27 were Avon Products (AVP), Kroger (KR), and Endo International (ENDP).

    By Renee Blakely
  • uploads///Tyson Foods TSN versus Kellogg K
    Macroeconomic Analysis

    Tyson Foods (TSN) Leads SPY on Quarterly Gains

    On November 23, Tyson Foods (TSN) closed at $48.09, which is well above its 100-day, 50-day, and 20-day moving averages of $44, $44, and $45, respectively

    By Renee Blakely
  • uploads///Tenet Healthcare Corp versus UnitedHealth Group
    Macroeconomic Analysis

    J.M. Smucker Led the SPY ETF with a 7.0% Gain

    J.M. Smucker posted EPS of $1.62, beating the consensus estimate of $1.52. It also reported net sales of ~$2.1 billion, in line with the market expectation.

    By Renee Blakely
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Anacor: Top Performer among Mid-Cap Stocks

    Anacor has a market cap of ~$4.63 billion, with a YTD return of 225.6% as on November 12. The company’s peers include Allergan and Mallinckrodt Public.

    By Peter Neil
  • uploads///Plum Creek Timber versus Weyerhaeuser
    Miscellaneous

    Weyerhaeuser on Its Way to Acquire Plum Creek Timber

    Stocks at the top of the SPY ETF on November 9 were Plum Creek Timber, Apache, and Norfolk Southern. They gained 17.3%, 13.2%, and 11.0%, respectively.

    By Renee Blakely
  • uploads///Performance of SPYs Component Sectors
    Macroeconomic Analysis

    Healthcare and Technology Stocks Weigh Down SPY

    The technology sector fell by 0.26% on October 20. Giant tech companies’ stocks fell including Micron Technology, Western Digital, Google, and IBM.

    By Renee Blakely
  • uploads///Liquidity
    Macroeconomic Analysis

    Introducing Liquidity: Must-Know Ins and Outs

    Liquidity, or “financial market liquidity,” refers to the ease with which you can buy or sell a security in financial markets at minimal cost.

    By David Ashworth
  • uploads///US High Yield Bond Fund Flows
    Company & Industry Overviews

    High Yield Bond Funds See Inflows after 2 Weeks of Outflows

    Investor flows in high yield bond funds turned positive last week after two successive weeks of outflows.

    By David Ashworth
  • uploads///Junk Bond Yields in  and
    Company & Industry Overviews

    Frontier Communications Was the Highest Issuer of Junk Bonds

    Junk bond issuers came back to the primary market in the week ended September 11, 2015, after two weeks of no issuance.

    By David Ashworth
  • uploads///Graph Part
    Company & Industry Overviews

    PerkinElmer and Mallinckrodt Help Bottom Ten Stocks in XLV

    PerkinElmer (PKI) with a return of 5.94% was the best performer of XLV’s bottom ten stocks.

    By Peter Neil
  • uploads///Margins
    Earnings Report

    Why Teva’s Generic Medicines Profitability Improved in 1Q15

    Teva’s increased profitability for its generic medicines was partially offset by decreased profitability of its specialty medicines, which were down by 13% in 1Q15 from 1Q14.

    By Nicole Sario
  • uploads///Generics Profitability
    Earnings Report

    Teva 1Q15 Earnings Preview: Profitability Drivers

    Teva plans to reduce the cost per tablet unit from $15 to $10. It’s shifting manufacturing operations to low-cost areas to improve product profitability.

    By Nicole Sario
  • uploads///US High Yield Bond Fund Flows
    Company & Industry Overviews

    High-Yield Bond Funds See Inflows Pick Up Pace in April 10 Week

    The largest issuers of high-yield bonds in the primary market last week were Fiat Chrysler Automobiles, GM Financial, and Mallinckrodt International.

    By David Ashworth
  • uploads///Junk Bond Yields in  and
    Company & Industry Overviews

    Fiat Chrysler, GM Financial Issue Largest Bonds in April 10 Week

    Investors showed interest in high-yield bonds in the week ended April 10. Fiat Chrysler issued B2/BB- rated junk bonds worth $3 billion.

    By David Ashworth
  • uploads///US High Yield Bond Market Issuance
    Company & Industry Overviews

    High-Yield Debt Issuance Gathers Steam in Week to April 10

    In the week to April 10, junk bonds, or high-yield debt issuers, returned to the primary market. It was the same week the FOMC released its March 2015 meeting minutes.

    By David Ashworth
  • uploads///Combined product portfolio
    Fund Managers

    Magnetar Capital Raises Its Stake in Actavis

    In the fourth quarter, Magnetar increased its exposure to Actavis. It bought 42,107 shares in the pharmaceutical firm. It represents 1.5% of the fund’s 4Q14 portfolio.

    By Santiago Solari
  • uploads///Risk Exposure
    Company & Industry Overviews

    Teva’s Risk Exposure in a Dynamic Environment

    Teva operates in a dynamic environment with a number of risks that could have a material adverse effect on the company.

    By Nicole Sario
  • uploads///Business Model
    Company & Industry Overviews

    Why Teva’s Business Model Is Progressively Evolving

    Teva intends to target a minimum annual profit of $4.3 billion, or $5 EPS, through 2016. To achieve this, Teva is reorienting its business model.

    By Nicole Sario
  • uploads///First to files
    Company & Industry Overviews

    Actavis Focuses on Complex Generics and Para IV Filings

    In January 2015, Actavis launched a generic specialty injectable portfolio, containing ~20 products across its therapeutic segments in the US.

    By Nicole Sario
  • uploads///Combined product portfolio
    Company & Industry Overviews

    How Actavis and Allergan Merger May Boost Branded Business

    Actavis intends to invest ~$1.7 billion in R&D annually. It expects to add ~15 projects in near- and mid-term development to the company’s product pipeline.

    By Nicole Sario
  • uploads///DUK
    Fund Managers

    Adage Capital adds stake in Duke Energy

    Adage Capital added a new position in Duke Energy in the third quarter. The position accounted for 0.20% of the fund’s total 3Q portfolio.

    By Samantha Nielson
  • uploads///TRW
    Fund Managers

    TRW Automotive Holdings is Adage Capital’s new position

    Adage Capital added a new position in TRW Automotive Holdings, which accounted for 0.32% of the fund’s total 3Q14 portfolio.

    By Samantha Nielson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.